Cem Zorlular, CEO of Er-Kim, explains how biotech can turn the new EU pharma package from challenge to opportunity.  In 2028, when new legislation takes effect, the European pharmaceutical landscape will undergo its most significant transformation in two decades. For biotechs, the new EU pharma package is not just a regulatory update; it is a […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!